Media coverage about Kindred Biosciences (NASDAQ:KIN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.5183790205509 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several equities analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of Kindred Biosciences in a research note on Friday, November 17th. They set a “buy” rating and a $9.50 price target on the stock. Aegis reissued a “buy” rating on shares of Kindred Biosciences in a research report on Friday, December 15th. Zacks Investment Research lowered shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, September 23rd. ValuEngine lowered shares of Kindred Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, B. Riley reissued a “buy” rating and set a $11.00 price objective on shares of Kindred Biosciences in a report on Monday, November 20th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $9.63.
Shares of Kindred Biosciences (NASDAQ:KIN) traded down $0.10 on Monday, hitting $8.85. 55,600 shares of the stock traded hands, compared to its average volume of 66,300. The firm has a market cap of $249.20, a PE ratio of -7.56 and a beta of 0.18. Kindred Biosciences has a 12 month low of $5.00 and a 12 month high of $9.80.
In other news, Director Raymond Townsend sold 6,419 shares of Kindred Biosciences stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $9.45, for a total value of $60,659.55. Following the transaction, the director now directly owns 18,419 shares of the company’s stock, valued at $174,059.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 19.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/kindred-biosciences-kin-earning-somewhat-favorable-press-coverage-accern-reports/1818068.html.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.